212 related articles for article (PubMed ID: 24815321)
1. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
Sobczak M; Cami-Kobeci G; Sałaga M; Husbands SM; Fichna J
Eur J Pharmacol; 2014 Aug; 736():63-9. PubMed ID: 24815321
[TBL] [Abstract][Full Text] [Related]
2. Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.
Zielińska M; Jarmuż A; Wasilewski A; Cami-Kobeci G; Husbands S; Fichna J
Pharmacol Rep; 2017 Apr; 69(2):350-357. PubMed ID: 28187396
[TBL] [Abstract][Full Text] [Related]
3. Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
Zielińska M; Jarmuż A; Sałaga M; Lipkowski AW; Fichna J
Pharmacol Rep; 2016 Feb; 68(1):32-6. PubMed ID: 26721348
[TBL] [Abstract][Full Text] [Related]
4. Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome.
Zielińska M; Chen C; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Sałaga M; Małecka-Panas E; Wlaź P; Krajewska WM; Fichna J
J Pharm Pharmacol; 2015 Feb; 67(2):244-54. PubMed ID: 25515402
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.
Zielińska M; Ben Haddou T; Cami-Kobeci G; Sałaga M; Jarmuż A; Padysz M; Kordek R; Spetea M; Husbands SM; Fichna J
Eur J Pharmacol; 2015 Oct; 765():582-90. PubMed ID: 26404500
[TBL] [Abstract][Full Text] [Related]
6. Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS.
Fichna J; Sobczak M; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Cenac N; Sałaga M; Timmermans JP; Vergnolle N; Małecka-Panas E; Krajewska WM; Storr M
Neurogastroenterol Motil; 2014 Nov; 26(11):1539-50. PubMed ID: 25041572
[TBL] [Abstract][Full Text] [Related]
7. Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract.
Szymaszkiewicz A; Włodarczyk J; Wasilewski A; Di Marzo V; Storr M; Fichna J; Zielińska M
Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1357-1364. PubMed ID: 32002574
[TBL] [Abstract][Full Text] [Related]
8. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Sałaga M; Polepally PR; Sobczak M; Grzywacz D; Kamysz W; Sibaev A; Storr M; Do Rego JC; Zjawiony JK; Fichna J
J Pharmacol Exp Ther; 2014 Jul; 350(1):69-78. PubMed ID: 24891526
[TBL] [Abstract][Full Text] [Related]
9. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Salaga M; Binienda A; Tichkule RB; Thakur GA; Makriyannis A; Storr M; Fichna J
Eur J Pharmacol; 2018 Oct; 836():34-43. PubMed ID: 30121173
[TBL] [Abstract][Full Text] [Related]
10. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
11. Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner.
Chen C; Lu M; Pan Q; Fichna J; Zheng L; Wang K; Yu Z; Li Y; Li K; Song A; Liu Z; Song Z; Kreis M
PLoS One; 2015; 10(12):e0145556. PubMed ID: 26700862
[TBL] [Abstract][Full Text] [Related]
12. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome.
Zhou TR; Huang JJ; Huang ZT; Cao HY; Tan B
World J Gastroenterol; 2018 Feb; 24(6):693-705. PubMed ID: 29456408
[TBL] [Abstract][Full Text] [Related]
14. G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain.
Zielińska M; Fichna J; Bashashati M; Habibi S; Sibaev A; Timmermans JP; Storr M
Neurogastroenterol Motil; 2017 Jul; 29(7):. PubMed ID: 28191706
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases.
Sobczak M; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Sałaga M; Storr M; Kordek R; Małecka-Panas E; Krajewska WM; Fichna J
J Pharmacol Exp Ther; 2014 Mar; 348(3):401-9. PubMed ID: 24345466
[TBL] [Abstract][Full Text] [Related]
16. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
17. Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission.
Fichna J; Poole DP; Veldhuis N; MacEachern SJ; Saur D; Zakrzewski PK; Cygankiewicz AI; Mokrowiecka A; Małecka-Panas E; Krajewska WM; Liedtke W; Steinhoff MS; Timmermans JP; Bunnett NW; Sharkey KA; Storr MA
J Mol Med (Berl); 2015 Dec; 93(12):1297-309. PubMed ID: 26330151
[TBL] [Abstract][Full Text] [Related]
18. Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome.
Sałaga M; Kowalczuk A; Zielinska M; Błażewicz A; Fichna J
Naunyn Schmiedebergs Arch Pharmacol; 2015 Oct; 388(10):1069-77. PubMed ID: 26068703
[TBL] [Abstract][Full Text] [Related]
19. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.
Wade PR; Palmer JM; McKenney S; Kenigs V; Chevalier K; Moore BA; Mabus JR; Saunders PR; Wallace NH; Schneider CR; Kimball ES; Breslin HJ; He W; Hornby PJ
Br J Pharmacol; 2012 Nov; 167(5):1111-25. PubMed ID: 22671931
[TBL] [Abstract][Full Text] [Related]
20. The role of Cortistatin-14 in the gastrointestinal motility in mice.
Jiang J; Jin W; Peng Y; Liang X; Li S; Wei L; Lei Z; Li L; Chang M
Pharmacol Rep; 2018 Apr; 70(2):355-363. PubMed ID: 29477944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
